Menu
Milan - Italy, June 16, 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today at the European Human Genetics Conference (ESHG 2018)that it has completed the acquisition of French-based tech company Interactive Biosoftware (IBS), the creators of Alamut® , the most used decision support software for clinical genomic data interpretation.
Alamut® is currently deployed in over 450 hospitals and is highly complementary to SOPHiA GENETICS’ offering. This is an important milestone that will further accelerate the adoption of Data-Driven Medicine around the world.
The acquisition reinforces SOPHiA GENETICS’ commitment to continuously support hospitals and patients with powerful technologies. Interactive Biosoftware’s expertise and teams will join SOPHiA GENETICS’ workforce. A seamless onboarding will ensure Alamut® users’ experience.
“Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs. It is great to join SOPHiA GENETICS unique approach and position to accelerate Data-Driven Medicine’sadoption.” – André Blavier CEO & Founder at Interactive Biosoftware.
“We are very excited about the acquisition of Interactive Biosoftware. Both SOPHiA AI and Alamut® are technologies trusted by the healthcare community and focus on patient-centric innovation. The addition of Alamut® marks a big step in our aim to help clinicians better diagnose patients equally. With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge.” - Jurgi Camblong, CEO & Co-founder at SOPHiA GENETICS.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
